Enavate Sciences

Patient Square Capital established Enavate Sciences as a separate operating entity in 2022 with approximately $300 million in committed capital. Patient Square remains the sole capital provider, but Enavate operates independently with its own management team and investment committee. The structure allows Enavate to focus exclusively on acquiring and building therapeutic programs, while Patient Square continues its broader healthcare private equity strategy.

Enavate Sciences does not invest in third-party venture funds. The firm makes direct equity investments, taking controlling or significant minority positions in therapeutic programs and platform companies. Enavate also structures in-licensing deals and university partnerships, such as its disclosed collaboration with Yale University on a neuroinflammation program.

Enavate targets preclinical and early clinical-stage programs that have scientific validation but require operational and strategic resources to reach proof of concept. The firm builds companies around assets — sometimes licensing a program from an academic lab and assembling the startup team internally — rather than writing checks into existing management-led rounds. It will also acquire de-prioritized clinical assets from larger pharmaceutical companies.

James Healy, a managing partner and former managing director at Patient Square Capital, leads Enavate's investment and operational decisions. Prior to Patient Square, Healy held senior investment roles at Sofinnova Investments and was a partner at Redmile Group, where he focused on public and private biotech. His background spans venture creation and asset-centric drug development.

Enavate is modality-agnostic and will pursue small molecules, biologics, cell therapies, and gene therapies where the underlying biology is compelling. Publicly disclosed portfolio programs span gene therapy for neuro-oncology (Disco Therapeutics) and small-molecule approaches in neuroinflammation. The firm has indicated openness to nucleic-acid therapeutics and radiopharmaceuticals as well.

Enavate has not publicly disclosed a co-investment model with external venture firms. The firm typically takes control or lead-investor positions and builds syndicates when seeking additional capital for clinical development. Their Patient Square Capital backing gives them the balance sheet to avoid syndication until later value-inflection points.

There is no public record of a separately structured philanthropic foundation tied directly to Enavate Sciences. Patient Square Capital does not operate a dedicated foundation, though individual partners may engage in personal philanthropy. Enavate's operational focus remains on commercial drug development.